Skip to main content

Cardiovascular Risk Factor

2
Pipeline Programs
6
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

LIB Therapeutics
LIB TherapeuticsOH - Cincinnati
1 program
1
lerodalcibepPhase 3
Medpace
MedpaceCINCINNATI, OH
1 program
1
lerodalcibepPhase 31 trial
Active Trials
NCT04806893Unknown900Est. Feb 2024
Innovation Pharmaceuticals
1 program
Nutritional intervention with Fermented Seaweed Enriched English Breakfast TeaN/A1 trial
Active Trials
NCT07070635Recruiting44Est. Nov 2025
Physiowave
PhysiowaveAustralia - Melbourne
1 program
PhysioWave Cardiovascular AnalyzerN/A1 trial
Active Trials
NCT03126994Completed160Est. May 2017
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Positron Emission TomographyN/A1 trial
Active Trials
NCT03388788Active Not Recruiting16Est. Jun 2026
Martin Pharmaceuticals
1 program
inorganic phosphateN/A1 trial
Active Trials
NCT03771924Completed29Est. Jan 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Medpacelerodalcibep
Innovation PharmaceuticalsNutritional intervention with Fermented Seaweed Enriched English Breakfast Tea
Martin Pharmaceuticalsinorganic phosphate
Oregon TherapeuticsPositron Emission Tomography
PhysiowavePhysioWave Cardiovascular Analyzer

Clinical Trials (5)

Total enrollment: 1,149 patients across 5 trials

NCT04806893Medpacelerodalcibep

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Start: Apr 2021Est. completion: Feb 2024900 patients
Phase 3Unknown
NCT07070635Innovation PharmaceuticalsNutritional intervention with Fermented Seaweed Enriched English Breakfast Tea

Abertay Tea for Cardiovascular Health During Menopause

Start: Jun 2025Est. completion: Nov 202544 patients
N/ARecruiting
NCT03771924Martin Pharmaceuticalsinorganic phosphate

Postprandial Response of Individuals to Dietary Inorganic Phosphate

Start: Aug 2018Est. completion: Jan 202029 patients
N/ACompleted
NCT03388788Oregon TherapeuticsPositron Emission Tomography

Body Weight, Sleep, and Heart Health

Start: May 2018Est. completion: Jun 202616 patients
N/AActive Not Recruiting
NCT03126994PhysiowavePhysioWave Cardiovascular Analyzer

Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer

Start: Apr 2017Est. completion: May 2017160 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,149 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.